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Abstract 
Gliosarcomas  (GS)  are  highly  malignant
and rare tumors of the central nervous system
with a poor prognosis. We report here on four
patients  with  GS,  the  median  survival  for
whom  was  9.25  months.  Prognosis  of  GS
remains  poor,  and  a  multidisciplinary
approach  (surgery,  radiation  therapy,  and
chemo  therapy)  seems  to  be  associated  with
slightly more prolonged survival times. 
Introduction 
Gliosarcomas  (GS)  are  highly  malignant
and rare tumors of the central nervous system
with a poor prognosis. They account for 2-8%
of  all  glioblastoma  multiforme  (GBM),  and
0.48% of all intracranial tumors.
1-4 They are pri-
mary brain tumors characterized by a biphasic
pattern displaying both glial and mesenchymal
components.
5 GS  are  predominant  in  males,
and usually affect patients in the fifth to sixth
decades of life. The clinical presentation, nat-
ural history, and radiologic profile are similar
to those of primary glioblastoma.
2,6,7
The clinical presentation varies according to
location  and  tumor  size.  The  most  common
symptoms  are  seizures,  focal  neurological
deficits, headache, and other symptoms relat-
ed to increased intracranial pressure.
7,8 Treat  -
ment includes tumor resection, postoperative
radiation therapy, and sometimes chemothera-
py.
4,8 At present, radiation therapy (60-66 Gy in
30 fractions) and chemotherapy are the stand  -
ard of care for GB and, consequently, for GS.
9,10
Between January 1999 and October 2004, 66
patients  underwent  radiation  therapy  for
newly  diagnosed  GBM  at  the  Department  of
Radiation Therapy, University of Ankara. We
report here on four patients with GS, retrieved
from this series. The aim of this retrospective
study is to analyze clinical features, treatment,
and survival. 
Materials and Methods 
Patients 
In the GS group, two patients were male and
two were female. The mean age was 56.5±4.65
years  (range,  50-61  years).  Three  of  the
patients had headache, one had motor deficit,
and  all  were  on  steroid  medication  during
treatment. Preoperative computed tomography
(CT)  scans  or  magnetic  resonance  imaging
(MRI) was performed in all patients (Figure
1). The locations, all supratentorial, included
left temporal in one, left frontoparietal in two,
and right frontoparietal areas and corpus callo-
sum in one patient (Figure 2). Midline shift
was not observed. 
Treatment 
All of the patients underwent tumor resec-
tion, which was classified as gross total. The
median interval between surgery and the initi-
ation  of  radiation  therapy  was  29.5  days
(range, 19-38 days). All patients were treated
with  Cobalt.
60 Clinical  Target  Volume  (CTV)
was established as Gross Tumor Volume (GTV)
plus  2-2.5  cm,  and  0.5  cm  was  added  as  a 
safety  margin  for  Planning  Target  Volume
(PTV).  All  of  the  patients  in  the  GS  group
received 60 Gy in 30 fractions. Three patients
had  chemotherapy  with  temozolomide.  All
cases tolerated radiation therapy well, without
interruption of their treatment because of side
effects. 
Statistics 
Survival was calculated from the first day of
radiation therapy, using the method of Kaplan
and Meier.
11
Results 
Clinical features 
Patient characteristics are shown in Table 1. 
Survival 
All patients in the GS group had died at the
time of analysis. The median survival was 9.25
months. 
Discussion 
In our present report, GS accounted for 5.5%
of  all  GBM,  with  a  mean  age  of  56.5±4.65
years. The age distribution was similar to that
of GBM patients. Other reported series deter-
mined that GS account for 2-8% of all GBM
with ages ranging from the fifth to the sixth
decades.
1-4,12,13 This is in accordance with our
findings (Table 1). GS reportedly affect males
more frequently than females.
2,4 However, the
male to female ratio was 2:2 in our GS group;
we  failed  to  observe  a  male  preponderance.
Furthermore,  although  a  temporal  lobe
predilection  has  been  reported  by  other
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Figure  1.  Cranial  magnetic  resonance
image of Case #1.
Figure  2.  Cranial  magnetic  resonance
image of Case #3.[page 102] [Rare Tumors 2010; 2:e37]
authors,
2,13 the majority of our GS patients pre-
sented  with  frontoparietal  lesions,  but  the
small numbers in our study make this difficult
to  interpret.  In  spite  of  some  reports  of
metastatic spread,
13,14none of the tumors of our
patients evolved with systemic dissemination. 
Several  authors  reported  significant
biologic  al  similarities  in  the  behavior  of  GS
and GBM,
2,4,6,13 suggesting that the same treat-
ment should be applied for these two kinds of
tumor.  On  the  basis  of  this  observation,  we
have treated patients with GS as those with
GBM. All of our GS patients underwent gross
total resection and all had postoperative radia-
tion therapy. The median interval between sur-
gery and the initiation of radiation therapy was
29.5  days  (range,  19-38  days).  Three  of  the
four  patients  received  chemotherapy  with
temozolomide, and one had no chemotherapy
because  of  her  poor  clinical  condition
(Karnofsky Performance Status 40). 
Morantz et al.
3 commented on the effect of
chemotherapy on the outcome. They found a
mild increase in survival in GS patients with
additional chemotherapy (36 weeks) compared
with  radiation  therapy  alone  (33  weeks).  In
our study, median survival was 9.25 months for
our  patients.  The  median  survival  in  GS
patients ranges from 6 to 14.8 months in the
reported studies.
1,3,4,13,15,16 It has to be noted that
survival times were calculated from different
points of time: date of onset, diagnosis, sur-
gery, or first day of radiation therapy. Heesters
et  al.
17 reported  a  median  survival  of  seven
months for their six GS patients. Lutterbach et
al.
4 analyzed  12  GS  patients  and  410  GBM
patients and found that the median survival
was 11.5 months for the GS patients compared
with  8.1  months  for  the  entire  GBM  group.
Perry  et  al.
13 analyzed  25  GS  patients  and
reported a median survival of six months. Meis
et al.
2 analyzed 26 GS patients and 1453 GBM
patients and report a median survival of 8.3
months  for  GS  patients  compared  with  9.6
months for the GBM patients; their findings
were contrary to the other reports. 
In the reported studies,
3,4,13 all patients died
within 20 months. In the study of Galanis et
al.,
12 only one of 18 patients survived for 29
months. Winkler et al.
18 presented a rare case
of GS in a 61-year-old woman who was stable
over 22 years. We concluded that despite the
fact that our cases were very few, the present-
ing clinical features, treatment, and survival of
GS are similar to that of GBM. Although the
prognosis of GS remains poor, a multidisciplin  -
ary approach (surgery, radiation therapy, and
chemotherapy)  seems  to  be  associated  with
slightly more prolonged survival times. 
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Case Report
Table 1. Characteristics, treatment, and survival of patients in the gliosarcoma group. 
Case  Age Sex  Presenting Site of lesion  Tumor size Resection  S-RT RT  CT  Survival
symptoms (cm) (days)  (months)
1  58  Male  Headache  Left temporal  Unknown Gross  38  +  +  6 months 
2  50  Female  Headache  Left frontoparietal  3¥3¥4  Gross  27  +  – 2.5 months 
3  57  Female  Motor deficit  Right frontoparietal and  3.5¥2.8¥3.2  Gross  32  +  +  12.5 months
corpus callosum  1.8¥1¥1 
4  61  Male  Headache  Left frontoparietal  6.5x3.5x3  Gross  19  +  +  22 months 
S, surgery; RT, radiation therapy; CT, chemotherapy; S-RT, interval surgery-radiation therapy; Gross, gross total resection. 